Clinical Trial

Trial Protocol ID USOR 23328_1479-0009 *STAR*

Trial Description

A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours 

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • John Wallmark, MD

Disease Types

Sponsor

  • BOEHRINGER INGELHEIM

ClinicalTrials.gov NCT ID

  • NCT06581432